Lacosamide Zentiva

Lacosamide, the active ingredient in Lacosamide Zentiva, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for adjunctive therapy of partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency when added to existing antiepileptic regimens and significantly improving overall seizure control.

GNH USA supplies Lacosamide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory compliance and on‑time delivery across global markets.

Lacosamide is an anticonvulsant used in the management of epilepsy, specifically targeting focal seizure activity.

- Partial‑onset seizures: reduces seizure frequency when used as add‑on therapy - Focal epilepsy: improves seizure control as adjunctive treatment - Adjunctive therapy in epilepsy: complements existing antiepileptic regimens to achieve better seizure management

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Suicidal ideation or behavior - Severe allergic reactions (e.g., angioedema, anaphylaxis) - Cardiac arrhythmias, including atrioventricular block - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatotoxicity or elevated liver enzymes - Respiratory depression in combination with CNS depressants

When prescribing Lacosamide, clinicians should consider several safety aspects.

- Renal impairment: assess kidney function and adjust dosing if necessary - Hepatic impairment: monitor liver enzymes regularly - Cardiac conduction disorders: avoid use in patients with known PR‑interval prolongation - Pregnancy: safety not established; use only if potential benefit outweighs risk - Concomitant CNS depressants: monitor for additive sedation or respiratory effects - Store at ambient temperature: keep below 25°C, protect from moisture and light

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide effectiveness

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate, phenytoin): may require dose adjustments - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation - QT‑prolonging agents: monitor cardiac rhythm for potential arrhythmias